Hardisty C A, Hanford L, Humphries H, Munro D S
Clin Endocrinol (Oxf). 1981 Jun;14(6):631-9. doi: 10.1111/j.1365-2265.1981.tb02975.x.
The prevalence of serum LATS and LATS-P in untreated Graves' disease has been studied in eighty-three patients with thyroid overactivity; twelve (14%) were found to have significant levels of LATs and LATS-P whilst fifty-nine (72%) had significant levels of LATS-P alone. Twelve (14%) had neither activity. There was a very wide range in both activities. LATS was invariably found in association with a significantly greater concentration of LATS-P. There was no correlation between LATS-P and thyroid mass, as estimated from scintiscanning, thyroidal radioiodine uptake at 4 and 48 h, total serum T4 and total serum T3. Neither LATS nor LATS-P were detected in eleven patients with toxic multinodular goitre nor four with solitary toxic adenoma.
对83例甲状腺功能亢进患者进行了研究，以检测未经治疗的格雷夫斯病患者血清长效甲状腺刺激素（LATS）和长效甲状腺刺激素保护物（LATS-P）的患病率；发现12例（14%）患者的LATS和LATS-P水平显著升高，而59例（72%）患者仅LATS-P水平显著升高。12例（14%）患者两者均无活性。两种活性的范围都非常广泛。LATS总是与显著更高浓度的LATS-P同时存在。根据闪烁扫描、4小时和48小时甲状腺放射性碘摄取、总血清T4和总血清T3估计，LATS-P与甲状腺大小之间无相关性。11例毒性多结节性甲状腺肿患者和4例孤立性毒性腺瘤患者均未检测到LATS和LATS-P。
